Nasdaq
$49.60▼ 0.94%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.61BShares out 93.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
33- 5d agoAfter-hours26.10.20 05:054Ownership#●●●
Travere Therapeutics, Inc.
Eric M. Dube, CEO of Travere Therapeutics, executed an insider transaction involving company shares on October 15, 2026. This filing reports the change in the executive's beneficial ownership to the SEC.…more
$49.60-0.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.15After-hours26.10.16 05:40144Ownership
Travere Therapeutics, Inc.
Eric M. Dube, CEO of Travere Therapeutics, has filed an SEC Form 144 to report a proposed sale of company shares. This filing serves as a standard notification of an insider's plan to dispose of their holdings.…more
$49.60-0.94%vs prev closeView filingShare - 9.21After-hours26.09.22 05:108-KKey event
Travere Therapeutics, Inc.
Travere Therapeutics announced that current CEO Eric Dube will step down effective December 1, 2026, and will be succeeded by Bradley L. Campbell. Dr. Dube will continue as an Executive Advisor until February 15, 2027, to facilitate a smooth transition.…more
$49.60-0.94%vs prev closeView filingShare
32 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.13Regular26.10.14 00:03#●●●#●●●
FTC Accuses Martin Shkreli of Violating Lifetime Pharma Ban
The FTC has filed a motion for civil contempt against Martin Shkreli, alleging he repeatedly violated a lifetime ban from the pharmaceutical industry by trading biotech stocks. Regulators are seeking the divestment of his pharmaceutical holdings and the disgorgement of trading profits.…more
$49.60-0.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.23Pre-market26.09.23 20:07
●●●●●●●● ●●●●● ●●●●●●
Travere Therapeutics announced that the USPTO has allowed a patent for its FSGS treatment, FILSPARI. This patent provides market exclusivity and coverage for the drug until October 2037.…more
$49.60-0.94%vs prev closeShareBenzinga - 9.21After-hours26.09.22 05:06
●●●●●●●● ●●●●● ●●●●●●
Travere Therapeutics announced that Bradley L. Campbell will succeed Eric Dube as president and CEO, effective December 1. Dr. Dube will step down for personal reasons and serve as an executive advisor until February 2027 to ensure a smooth transition.…more
$49.60-0.94%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report